Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?  

Unfortunately, no great data yet, largely case series and retrospective observations. Our group presented data at the 2022 IMS meeting (Reyes et al., "Salvage Therapies and Clinical Outcomes After Relapse Following BCMA CAR-T in Patients with RRMM") showing a 75% ORR and median duration of response ...

I think there is an additional element that we must take into account, which is cost and scarcity. Right now, we have a paucity of data on whether treating with another BCMA-directed CAR T product will result in meaningful and durable responses. Should we really be prioritizing patients with prior r...